Developer docs
API playgroundTry for free, no card

Search company profiles

Walvax Biotechnology

Full company profile

uuid003ed2j

Namestring
Walvax Biotechnology
Legal namestring
云南沃森生物技术股份有限公司
Websiteurl
walvax.com
Company typeenum
Public
Founded yearint
2001
Descriptiontext

Walvax Biotechnology Co., Ltd. (云南沃森生物技术股份有限公司) is a publicly listed Chinese vaccine manufacturer (Shenzhen Stock Exchange, ticker 300142.SZ, ChiNext board) founded in 2001 and headquartered in Kunming, Yunnan Province. The company develops, manufactures, and commercializes a portfolio of nine licensed vaccines (13 presentations) spanning conjugate, polysaccharide, recombinant subunit, and mRNA platforms. Core commercial products include PCV13 (second approved 13-valent pneumococcal conjugate vaccine globally), the world's first preservative-free PPSV23, Hib vaccine, AC and ACYW135 meningococcal vaccines, DTaP, and Walrinvax — a Pichia pastoris-expressed bivalent HPV vaccine that became the first Chinese private-sector HPV vaccine to receive WHO prequalification in August 2024. The technology stack rests on proprietary conjugate vaccine chemistry, a Pichia pastoris recombinant expression system, a novel human diploid cell line (Walvax-2), CpG ODN adjuvant technology, and an mRNA vaccine platform with a 60-day lead time from DNA sequence to sample test.

Revenue derives from four streams: domestic Chinese vaccine sales via the National Immunization Program (NIP) and private market, international vaccine exports to 26 countries, technology transfer and licensing for local production in emerging markets, and international development funding from Gates Foundation and CEPI. Manufacturing capacity totals 390 million doses per year across facilities in Yuxi (128-acre, 148,000 sqm), Shanghai, Beijing, and Kunming, designed to China, EU, WHO GMP, PIC/S, and ISPE standards. GTM operates almost entirely through institutional channels: government tenders, UN procurement (UNICEF, PAHO), Gavi supply commitments, bilateral government-to-government agreements (Morocco, Indonesia, Egypt, Thailand, India, Uzbekistan), and technology transfer partnerships with local manufacturers (Pharmaniaga Malaysia, Etana Indonesia, Vacsera and VBC Egypt). The company employs 11-50 staff at the listed entity level (broader group headcount not disclosed), generated USD 344 million in 2025 revenue, ranks among WHO's Top 10 vaccine manufacturers by value (2022 excluding COVID-19), and has supplied over 270 million doses cumulatively to China and 17 developing countries.

Short descriptiontext

Walvax Biotechnology is a publicly listed Chinese vaccine manufacturer developing and commercializing conjugate, recombinant, and mRNA vaccines — including PCV13, WHO-prequalified bivalent HPV vaccine Walrinvax, and preservative-free PPSV23 — for sale through China's NIP, international government tenders, UN procurement, and technology transfer partnerships across 26 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersKunming, China
HQ citystring
Kunming
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
vaccine manufacturing, pneumococcal conjugate vaccines, HPV vaccines, mRNA vaccine technology, biologics manufacturing
Industry1 code
PRIMARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Vaccines
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Vaccine Sales (Domestic China)
TypeOne Time License
Description

Domestic vaccine sales through government procurement via National Immunization Program (NIP) and private market sales of non-EPI vaccines.

caixinglobal.com
2International Vaccine Export
TypeOne Time License
Description

Export of finished vaccine products and bulk drug substance to international markets including WHO prequalified product procurement, bilateral government contracts, and commercial sales through distributors.

walvax.com
3Technology Transfer and Licensing
TypeLicensing Royalties
Description

Revenue from technology transfer partnerships for local vaccine production in target markets such as Egypt, Indonesia, Malaysia, Uzbekistan.

walvax.com
4International Development Funding
TypeLicensing Royalties
Description

Project funding and grants from international organizations (Gates Foundation, CEPI) for vaccine development and WHO prequalification.

caspianpost.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Infrastructure, Supply Chain, Operations, Personnel, Marketing or Sales
Pricing details1 tier
1HPV vaccine government procurement pricing
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

China's nationwide free HPV vaccination program for 13-year-old girls announced to purchase 15.45 million doses at historical low prices, impacting domestic manufacturers including Walvax.

caixinglobal.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Walrinvax
Description

Prophylactic pichia pastoris-expressed bivalent (types 16 and 18) HPV vaccine developed by Shanghai Zerun Biotechnology, WHO prequalified in August 2024

en.walvax.com
+3 more records
Core offering1 text field

Walvax Biotechnology researches, develops, manufactures, and commercializes vaccines for infectious disease prevention. Its commercial portfolio includes 13-valent pneumococcal conjugate vaccine (PCV13), 23-valent pneumococcal polysaccharide vaccine (PPSV23), bivalent HPV vaccine (Walrinvax), Hib vaccine, meningococcal polysaccharide and conjugate vaccines (AC, ACYW135, MPV AC), DTaP vaccine, and SARS-CoV-2 mRNA vaccines (AWcorna, RQ3013). The company also generates revenue through technology transfer for local vaccine production in emerging markets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • PCV13 maintains leading market share in China since 2021
+4 more records
Product overview1 text field

Walvax Biotechnology is a leading Chinese vaccine manufacturer engaged in research and development, manufacturing, and distribution of safe and efficacious vaccines. The company has developed and commercialized multiple vaccine products across its portfolio: PCV13 (13-valent pneumococcal conjugate vaccine) for pediatric pneumococcal disease prevention, PPSV23 (23-valent pneumococcal polysaccharide vaccine) for broader serotype coverage, Hib vaccine, AC conjugate vaccine, MPV ACYW135 (quadrivalent meningococcal polysaccharide vaccine), Walrinvax (bivalent HPV vaccine using Pichia pastoris expression), MPV AC, and DTaP (diphtheria-tetanus-pertussis) vaccine. The company has also developed mRNA vaccine technology platforms producing AWcorna (COVID-19 mRNA vaccine) and RQ3013 (variant mRNA vaccine). Products span both immunogenicity program (EPI) vaccines and non-EPI (private market) vaccines. Walvax serves domestic China markets through provincial coverage and exports to over 26 countries globally.

Product and service10 records
113-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
CategoryPneumococcal conjugate vaccine
Description

13-valent pneumococcal conjugate vaccine for prevention of invasive diseases caused by 13 serotypes of Streptococcus pneumoniae in infants and children aged 6 weeks through 5 years; second approved 13-valent PCV in the world, using tetanus toxoid carrier protein.

223-valent Pneumococcal Polysaccharide Vaccine (PPSV23)
CategoryPneumococcal polysaccharide vaccine
Description

23-valent pneumococcal polysaccharide vaccine for prevention of pneumococcal diseases caused by 23 serotypes of Streptococcus pneumoniae in individuals aged 2 years and above; world's first preservative-free PPSV23.

3b-type Haemophilus influenzae Conjugate Vaccine (Hib Vaccine)
CategoryBacterial conjugate vaccine
Description

Hib vaccine for prevention of invasive infections caused by Haemophilus influenzae type b including meningitis, pneumonia, and septicemia, for infants aged 2 months through children aged 5 years.

4Group A and C Meningococcal Polysaccharide Conjugate Vaccine (AC Conjugate Vaccine)
CategoryMeningococcal conjugate vaccine
Description

AC group meningococcal polysaccharide conjugate vaccine for prevention of meningococcal meningitis and septicemia caused by Group A and Group C meningococcus, for children aged 3 months to 5 years.

5ACYW135 Group Meningococcal Polysaccharide Vaccine (MPV ACYW135)
CategoryMeningococcal polysaccharide vaccine
Description

Quadrivalent meningococcal polysaccharide vaccine for prevention of epidemic cerebrospinal meningitis caused by Group A, C, Y, and W135 meningococcus, for children aged 2 years and above and high-risk adults.

6Bivalent Human Papillomavirus Vaccine (Pichia pastoris) — Walrinvax / HPV-2
CategoryRecombinant HPV vaccine
Description

Bivalent HPV vaccine expressed in Pichia pastoris yeast for prevention of cervical cancer and precancerous lesions caused by HPV types 16 and 18, approved for females aged 9-30 years. WHO prequalified in August 2024.

7Group A and C Meningococcal Polysaccharide Vaccine (MPV AC)
8Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine (DTaP Vaccine)
9AWcorna (SARS-CoV-2 mRNA Vaccine)
CategorymRNA COVID-19 vaccine
Description

SARS-CoV-2 mRNA vaccine developed with Suzhou Abogen Biosciences, encoding the receptor-binding domain of the spike protein; demonstrated 83.58% efficacy against wild-type SARS-CoV-2 and 71.17% against Omicron variant; storage at 2-8°C.

10RQ3013 (SARS-CoV-2 Variant mRNA Vaccine)
Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
1Pharmaniaga Lifescience Sdn. Bhd. (Malaysia)
Strategic tierSignificantTypeStrategic or Co-development PartnerAnnounced on2025-10-24
Description

Agreement signed for finished product distribution and local production of PCV-13 in Malaysia, the 6th local production project following Morocco, Indonesia, Egypt, Mexico and Bangladesh. Facilitated by Dubai-based RevonBio FZ-LLC.

en.walvax.com
Strategic tierSignificantTypeStrategic or Co-development PartnerAnnounced on2025-07-17
Description

Discussions with Uzbekistan government delegation to establish local vaccine production, focusing on technology transfer, product registration, and partner selection for Central Asian market expansion.

Strategic tierSignificantTypeStrategic or Co-development PartnerAnnounced on2024-11-29
Description

MOU signed with Egyptian pharmaceutical company Vacsera for local production of meningococcal vaccines in Egypt as part of EVMA initiative.

4VBC (Vaccines and Biotechnology City, Egypt)
Strategic tierSignificantTypeStrategic or Co-development PartnerAnnounced on2024-11-29
Description

MOU signed with VBC for local production of PCV13 and HPV2 vaccines in Egypt, collaborating to build Egypt as Africa regional vaccine manufacturing hub.

en.walvax.com
5PT Etana Biotechnologies Indonesia
Strategic tierSignificantTypeStrategic or Co-development PartnerAnnounced on2022-11-13
Description

MOU signed at B20 Summit for localization of PCV and HPV vaccines in Indonesia. Second vaccine collaboration following COVID-19 mRNA vaccine partnership. Witnessed by Indonesian Minister of Health.

en.walvax.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-30
Description

Joint development of SARS-CoV-2 mRNA vaccine (AWcorna) with Abogen. Walvax provides manufacturing capability while Abogen provides mRNA technology platform. Indonesian EUA obtained September 2022.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-21
Description

CEPI partnership with Shanghai Zerun Biotech (Walvax subsidiary) providing $13.1 million initial funding, later expanded by $8.15 million additional investment totaling $25.1 million for COVID-19 prototype and variant vaccine development including Phase I clinical trials in Mali.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2020-06-03
Description

Walvax committed to supply over half of HPV vaccine production capacity to Gavi-supported countries at affordable prices. Commitment made at 2020 Global Vaccine Summit to provide sufficient supply for 84 million girls in Gavi countries.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

WHO prequalification achieved for HPV vaccine (Walrinvax) enabling UN procurement access. Ongoing collaboration for PQ process and engagement with WHO initiatives for vaccine equity.

Strategic tierCoreTypeGTM or Marketing Partner
Description

UNICEF procurement partnership for WHO prequalified vaccines. Walrinvax eligible for UNICEF procurement through Gavi-supported country programs.

11PATH
Strategic tierCoreTypeStrategic or Co-development Partner
Description

PATH providing technical assistance for Walrinvax WHO prequalification since 2017, including quality management, pharmacovigilance, and CMC support.

walvax.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

DCVMN membership with Mr. Andrew Wong serving as Board Member for 2023-2025 term, the only Chinese vaccine company representative on the board. Active participation in annual meetings and knowledge sharing.

13RevonBio FZ-LLC
Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Dubai-based commercial biologics enterprise supporting Walvax in commercializing products across emerging markets, including facilitation of Malaysia partnership.

en.walvax.com
14Shanghai RNACure Biopharma (RNAcure)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with RNAcure for SARS-CoV-2 variant mRNA vaccine RQ3013 development. Phase 3b clinical trial data published in eClinicalMedicine demonstrating superior immunogenicity as heterologous booster.

en.walvax.com
Strategic tierSupportingTypeTechnology or Integration
Description

Academic partnership for mRNA vaccine technology platform development and expertise sharing, along with collaboration on COVID-19 variant vaccine development.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Indian vaccine manufacturer with WHO-prequalified portfolio including rotavirus, typhoid, and COVID-19 vaccines. Comparable as an emerging market vaccine innovator with WHO prequalification focus, DCVMN membership, and global health organization partnerships.

2Biological E
TypeEmerging player
Description

Indian vaccine manufacturer expanding into PCV and other conjugate vaccines with WHO prequalification focus. Comparable as a developing country vaccine manufacturer pursuing the same WHO-PQ pathway and Gavi/UNICEF procurement access.

3China National Biotec Group (CNBG/Sinopharm)
TypeBroad incumbent
Description

State-owned largest Chinese vaccine manufacturer with extensive EPI portfolio including polio, measles, and COVID-19 vaccines. Competes with Walvax in NIP procurement and serves as the dominant domestic incumbent across most vaccine categories.

4Sinovac Biotech
TypeDirect peer
Description

Chinese vaccine manufacturer with broad portfolio including COVID-19, influenza, and hepatitis vaccines. Comparable in domestic market positioning, export focus to emerging markets, and platform breadth across inactivated, recombinant, and combination vaccines.

TypeDirect peer
Description

Chinese vaccine developer with adenovirus vector and mRNA platforms, including WHO-prequalified COVID-19 and meningitis vaccines. Comparable as a Chinese-listed vaccine innovator pursuing international WHO prequalification and emerging market expansion.

TypeBroad incumbent
Description

World's largest vaccine manufacturer by doses, supplying WHO/UNICEF/Gavi programs globally. Direct competitor in emerging market NIP procurement, with WHO-prequalified PCV and HPV products that overlap Walvax's portfolio priorities.

7Hualan Biological Engineering
TypeDirect peer
Description

Chinese vaccine and blood product manufacturer with influenza and other vaccine franchises. Comparable as a domestically focused vaccine company with similar scale, listed status on Chinese exchanges, and EPI program participation.

TypeDirect peer
Description

Major Chinese HPV vaccine distributor and competitor, controlling the agency rights for Merck's Gardasil in China. Direct competitor to Walrinvax in the Chinese HPV market with overlapping NIP procurement exposure.

TypeBroad incumbent
Description

Developer of Prevnar 13/20, the originator PCV products. Direct reference competitor for Walvax's PCV13, with Walvax's vaccine having demonstrated non-inferior immunogenicity to Pfizer's reference product.

TypeBroad incumbent
Description

Developer of Gardasil HPV vaccines. Walvax's Walrinvax competes with Merck's HPV franchise in global markets, particularly in emerging markets where Merck holds established supply agreements.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Walvax Biotechnology

Vaccineswalvax.com

Walvax Biotechnology is a publicly listed Chinese vaccine manufacturer developing and commercializing conjugate, recombinant, and mRNA vaccines — including PCV13, WHO-prequalified bivalent HPV vaccine Walrinvax, and preservative-free PPSV23 — for sale through China's NIP, international government tenders, UN procurement, and technology transfer partnerships across 26 countries.

What Walvax Biotechnology does

Walvax Biotechnology Co., Ltd. (云南沃森生物技术股份有限公司) is a publicly listed Chinese vaccine manufacturer (Shenzhen Stock Exchange, ticker 300142.SZ, ChiNext board) founded in 2001 and headquartered in Kunming, Yunnan Province. The company develops, manufactures, and commercializes a portfolio of nine licensed vaccines (13 presentations) spanning conjugate, polysaccharide, recombinant subunit, and mRNA platforms. Core commercial products include PCV13 (second approved 13-valent pneumococcal conjugate vaccine globally), the world's first preservative-free PPSV23, Hib vaccine, AC and ACYW135 meningococcal vaccines, DTaP, and Walrinvax — a Pichia pastoris-expressed bivalent HPV vaccine that became the first Chinese private-sector HPV vaccine to receive WHO prequalification in August 2024. The technology stack rests on proprietary conjugate vaccine chemistry, a Pichia pastoris recombinant expression system, a novel human diploid cell line (Walvax-2), CpG ODN adjuvant technology, and an mRNA vaccine platform with a 60-day lead time from DNA sequence to sample test.

Revenue derives from four streams: domestic Chinese vaccine sales via the National Immunization Program (NIP) and private market, international vaccine exports to 26 countries, technology transfer and licensing for local production in emerging markets, and international development funding from Gates Foundation and CEPI. Manufacturing capacity totals 390 million doses per year across facilities in Yuxi (128-acre, 148,000 sqm), Shanghai, Beijing, and Kunming, designed to China, EU, WHO GMP, PIC/S, and ISPE standards. GTM operates almost entirely through institutional channels: government tenders, UN procurement (UNICEF, PAHO), Gavi supply commitments, bilateral government-to-government agreements (Morocco, Indonesia, Egypt, Thailand, India, Uzbekistan), and technology transfer partnerships with local manufacturers (Pharmaniaga Malaysia, Etana Indonesia, Vacsera and VBC Egypt). The company employs 11-50 staff at the listed entity level (broader group headcount not disclosed), generated USD 344 million in 2025 revenue, ranks among WHO's Top 10 vaccine manufacturers by value (2022 excluding COVID-19), and has supplied over 270 million doses cumulatively to China and 17 developing countries.

Walvax Biotechnology firmographics

Firmographics
Name
Walvax Biotechnology
Legal name
云南沃森生物技术股份有限公司
Website
https://walvax.com
Company type
Public
Founded year
2001
Operating status
Operating
Headcount range
51–100 employees
Short description
Walvax Biotechnology is a publicly listed Chinese vaccine manufacturer developing and commercializing conjugate, recombinant, and mRNA vaccines — including PCV13, WHO-prequalified bivalent HPV vaccine Walrinvax, and preservative-free PPSV23 — for sale through China's NIP, international government tenders, UN procurement, and technology transfer partnerships across 26 countries.
Ownership category
akta.pro rank

Walvax Biotechnology industry classification

Industry
Product category
Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Vaccine manufacturing
  • Pneumococcal conjugate vaccines
  • HPV vaccines
  • MRNA vaccine technology
  • Biologics manufacturing

Where Walvax Biotechnology is headquartered

Location

Headquarters

HQ city
Kunming
HQ country
China
HQ region
Asia

Offices5 records

Markets served

Walvax Biotechnology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Infrastructure, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

  1. Vaccine Sales (Domestic China): Domestic vaccine sales through government procurement via National Immunization Program (NIP) and private market sales of non-EPI vaccines.
  2. International Vaccine Export: Export of finished vaccine products and bulk drug substance to international markets including WHO prequalified product procurement, bilateral government contracts, and commercial sales through distributors.
  3. Technology Transfer and Licensing: Revenue from technology transfer partnerships for local vaccine production in target markets such as Egypt, Indonesia, Malaysia, Uzbekistan.
  4. International Development Funding: Project funding and grants from international organizations (Gates Foundation, CEPI) for vaccine development and WHO prequalification.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractHPV vaccine government procurement pricing

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Walvax Biotechnology product offering

Product offering

Core offering

Walvax Biotechnology researches, develops, manufactures, and commercializes vaccines for infectious disease prevention. Its commercial portfolio includes 13-valent pneumococcal conjugate vaccine (PCV13), 23-valent pneumococcal polysaccharide vaccine (PPSV23), bivalent HPV vaccine (Walrinvax), Hib vaccine, meningococcal polysaccharide and conjugate vaccines (AC, ACYW135, MPV AC), DTaP vaccine, and SARS-CoV-2 mRNA vaccines (AWcorna, RQ3013). The company also generates revenue through technology transfer for local vaccine production in emerging markets.

Product overview

Walvax Biotechnology is a leading Chinese vaccine manufacturer engaged in research and development, manufacturing, and distribution of safe and efficacious vaccines. The company has developed and commercialized multiple vaccine products across its portfolio: PCV13 (13-valent pneumococcal conjugate vaccine) for pediatric pneumococcal disease prevention, PPSV23 (23-valent pneumococcal polysaccharide vaccine) for broader serotype coverage, Hib vaccine, AC conjugate vaccine, MPV ACYW135 (quadrivalent meningococcal polysaccharide vaccine), Walrinvax (bivalent HPV vaccine using Pichia pastoris expression), MPV AC, and DTaP (diphtheria-tetanus-pertussis) vaccine. The company has also developed mRNA vaccine technology platforms producing AWcorna (COVID-19 mRNA vaccine) and RQ3013 (variant mRNA vaccine). Products span both immunogenicity program (EPI) vaccines and non-EPI (private market) vaccines. Walvax serves domestic China markets through provincial coverage and exports to over 26 countries globally.

Differentiator

Problem solved

Functional benefit

Brands

  • Walrinvax: Prophylactic pichia pastoris-expressed bivalent (types 16 and 18) HPV vaccine developed by Shanghai Zerun Biotechnology, WHO prequalified in August 2024
  • Weuphoria
  • AWcorna
  • Walrinvax

Products and services

  • 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) 13-valent pneumococcal conjugate vaccine for prevention of invasive diseases caused by 13 serotypes of Streptococcus pneumoniae in infants and children aged 6 weeks through 5 years; second approved 13-valent PCV in the world, using tetanus toxoid carrier protein.
  • 23-valent Pneumococcal Polysaccharide Vaccine (PPSV23) 23-valent pneumococcal polysaccharide vaccine for prevention of pneumococcal diseases caused by 23 serotypes of Streptococcus pneumoniae in individuals aged 2 years and above; world's first preservative-free PPSV23.
  • b-type Haemophilus influenzae Conjugate Vaccine (Hib Vaccine) Hib vaccine for prevention of invasive infections caused by Haemophilus influenzae type b including meningitis, pneumonia, and septicemia, for infants aged 2 months through children aged 5 years.
  • Group A and C Meningococcal Polysaccharide Conjugate Vaccine (AC Conjugate Vaccine) AC group meningococcal polysaccharide conjugate vaccine for prevention of meningococcal meningitis and septicemia caused by Group A and Group C meningococcus, for children aged 3 months to 5 years.
  • ACYW135 Group Meningococcal Polysaccharide Vaccine (MPV ACYW135) Quadrivalent meningococcal polysaccharide vaccine for prevention of epidemic cerebrospinal meningitis caused by Group A, C, Y, and W135 meningococcus, for children aged 2 years and above and high-risk adults.
  • Bivalent Human Papillomavirus Vaccine (Pichia pastoris) — Walrinvax / HPV-2 Bivalent HPV vaccine expressed in Pichia pastoris yeast for prevention of cervical cancer and precancerous lesions caused by HPV types 16 and 18, approved for females aged 9-30 years. WHO prequalified in August 2024.
  • Group A and C Meningococcal Polysaccharide Vaccine (MPV AC)
  • Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine (DTaP Vaccine)
  • AWcorna (SARS-CoV-2 mRNA Vaccine) SARS-CoV-2 mRNA vaccine developed with Suzhou Abogen Biosciences, encoding the receptor-binding domain of the spike protein; demonstrated 83.58% efficacy against wild-type SARS-CoV-2 and 71.17% against Omicron variant; storage at 2-8°C.
  • RQ3013 (SARS-CoV-2 Variant mRNA Vaccine)

Quantifiable outcome

  • PCV13 maintains leading market share in China since 2021
  • +4 more outcomes

Companies that use Walvax Biotechnology

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Walvax Biotechnology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Walvax Biotechnology partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered significant, core and supporting.

  • Pharmaniaga Lifescience Sdn. Bhd. (Malaysia)significantStrategic or Co-development Partner · 24 October 2025Agreement signed for finished product distribution and local production of PCV-13 in Malaysia, the 6th local production project following Morocco, Indonesia, Egypt, Mexico and Bangladesh. Facilitated by Dubai-based RevonBio FZ-LLC.
  • Uzbekistan GovernmentsignificantStrategic or Co-development Partner · 17 July 2025Discussions with Uzbekistan government delegation to establish local vaccine production, focusing on technology transfer, product registration, and partner selection for Central Asian market expansion.
  • Vacsera (Egypt)significantStrategic or Co-development Partner · 29 November 2024MOU signed with Egyptian pharmaceutical company Vacsera for local production of meningococcal vaccines in Egypt as part of EVMA initiative.
  • VBC (Vaccines and Biotechnology City, Egypt)significantStrategic or Co-development Partner · 29 November 2024MOU signed with VBC for local production of PCV13 and HPV2 vaccines in Egypt, collaborating to build Egypt as Africa regional vaccine manufacturing hub.
  • PT Etana Biotechnologies IndonesiasignificantStrategic or Co-development Partner · 13 November 2022MOU signed at B20 Summit for localization of PCV and HPV vaccines in Indonesia. Second vaccine collaboration following COVID-19 mRNA vaccine partnership. Witnessed by Indonesian Minister of Health.
  • Suzhou Abogen Biosciences (Abogen)coreStrategic or Co-development Partner · 30 September 2022Joint development of SARS-CoV-2 mRNA vaccine (AWcorna) with Abogen. Walvax provides manufacturing capability while Abogen provides mRNA technology platform. Indonesian EUA obtained September 2022.
  • CEPI (Coalition for Epidemic Preparedness Innovations)coreStrategic or Co-development Partner · 21 July 2021CEPI partnership with Shanghai Zerun Biotech (Walvax subsidiary) providing $13.1 million initial funding, later expanded by $8.15 million additional investment totaling $25.1 million for COVID-19 prototype and variant vaccine development including Phase I clinical trials in Mali.
  • Gavi, the Vaccine AlliancecoreGTM or Marketing Partner · 3 June 2020Walvax committed to supply over half of HPV vaccine production capacity to Gavi-supported countries at affordable prices. Commitment made at 2020 Global Vaccine Summit to provide sufficient supply for 84 million girls in Gavi countries.
  • WHO (World Health Organization)coreStrategic or Co-development PartnerWHO prequalification achieved for HPV vaccine (Walrinvax) enabling UN procurement access. Ongoing collaboration for PQ process and engagement with WHO initiatives for vaccine equity.
  • UNICEFcoreGTM or Marketing PartnerUNICEF procurement partnership for WHO prequalified vaccines. Walrinvax eligible for UNICEF procurement through Gavi-supported country programs.
  • PATHcoreStrategic or Co-development PartnerPATH providing technical assistance for Walrinvax WHO prequalification since 2017, including quality management, pharmacovigilance, and CMC support.
  • DCVMN (Developing Countries Vaccine Manufacturers Network)coreStrategic or Co-development PartnerDCVMN membership with Mr. Andrew Wong serving as Board Member for 2023-2025 term, the only Chinese vaccine company representative on the board. Active participation in annual meetings and knowledge sharing.
  • RevonBio FZ-LLCsupportingChannel Partner/ Reseller/ DistributorDubai-based commercial biologics enterprise supporting Walvax in commercializing products across emerging markets, including facilitation of Malaysia partnership.
  • Shanghai RNACure Biopharma (RNAcure)coreStrategic or Co-development PartnerCollaboration with RNAcure for SARS-CoV-2 variant mRNA vaccine RQ3013 development. Phase 3b clinical trial data published in eClinicalMedicine demonstrating superior immunogenicity as heterologous booster.
  • Fudan UniversitysupportingTechnology or IntegrationAcademic partnership for mRNA vaccine technology platform development and expertise sharing, along with collaboration on COVID-19 variant vaccine development.

Scale indicators16 records

Recent moves8 records

Expansion highlights6 records

Walvax Biotechnology competitors and assessment

Company assessment

Direct peers

  • Bharat Biotech: Indian vaccine manufacturer with WHO-prequalified portfolio including rotavirus, typhoid, and COVID-19 vaccines. Comparable as an emerging market vaccine innovator with WHO prequalification focus, DCVMN membership, and global health organization partnerships.
  • Sinovac Biotech: Chinese vaccine manufacturer with broad portfolio including COVID-19, influenza, and hepatitis vaccines. Comparable in domestic market positioning, export focus to emerging markets, and platform breadth across inactivated, recombinant, and combination vaccines.
  • CanSino Biologics: Chinese vaccine developer with adenovirus vector and mRNA platforms, including WHO-prequalified COVID-19 and meningitis vaccines. Comparable as a Chinese-listed vaccine innovator pursuing international WHO prequalification and emerging market expansion.
  • Hualan Biological Engineering: Chinese vaccine and blood product manufacturer with influenza and other vaccine franchises. Comparable as a domestically focused vaccine company with similar scale, listed status on Chinese exchanges, and EPI program participation.
  • Zhifei Biological Products: Major Chinese HPV vaccine distributor and competitor, controlling the agency rights for Merck's Gardasil in China. Direct competitor to Walrinvax in the Chinese HPV market with overlapping NIP procurement exposure.

Emerging players

  • Biological E: Indian vaccine manufacturer expanding into PCV and other conjugate vaccines with WHO prequalification focus. Comparable as a developing country vaccine manufacturer pursuing the same WHO-PQ pathway and Gavi/UNICEF procurement access.

Broad incumbents

  • China National Biotec Group (CNBG/Sinopharm): State-owned largest Chinese vaccine manufacturer with extensive EPI portfolio including polio, measles, and COVID-19 vaccines. Competes with Walvax in NIP procurement and serves as the dominant domestic incumbent across most vaccine categories.
  • Serum Institute of India: World's largest vaccine manufacturer by doses, supplying WHO/UNICEF/Gavi programs globally. Direct competitor in emerging market NIP procurement, with WHO-prequalified PCV and HPV products that overlap Walvax's portfolio priorities.
  • Pfizer (Prevnar franchise): Developer of Prevnar 13/20, the originator PCV products. Direct reference competitor for Walvax's PCV13, with Walvax's vaccine having demonstrated non-inferior immunogenicity to Pfizer's reference product.
  • Merck (Gardasil franchise): Developer of Gardasil HPV vaccines. Walvax's Walrinvax competes with Merck's HPV franchise in global markets, particularly in emerging markets where Merck holds established supply agreements.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Walvax Biotechnology social profiles

Digital presence

Walvax Biotechnology compliance and trust

Trust signal

Compliance6 records

Walvax Biotechnology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Walvax Biotechnology leadership team

Management profile

Number of profiles

Profiles6 records

Walvax Biotechnology subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Walvax Biotechnology funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Walvax Biotechnology M&A and investment

M&A and investment

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Walvax Biotechnology

What does Walvax Biotechnology do?

Walvax Biotechnology researches, develops, manufactures, and commercializes vaccines for infectious disease prevention. Its commercial portfolio includes 13-valent pneumococcal conjugate vaccine (PCV13), 23-valent pneumococcal polysaccharide vaccine (PPSV23), bivalent HPV vaccine (Walrinvax), Hib vaccine, meningococcal polysaccharide and conjugate vaccines (AC, ACYW135, MPV AC), DTaP vaccine, and SARS-CoV-2 mRNA vaccines (AWcorna, RQ3013). The company also generates revenue through technology transfer for local vaccine production in emerging markets.

Is Walvax Biotechnology a public or private company?

Walvax Biotechnology is a public company. It is classified as public and is currently operating.

When was Walvax Biotechnology founded?

Walvax Biotechnology was founded in 2001. It employs 51 to 100 people.

Where is Walvax Biotechnology based?

Walvax Biotechnology is headquartered in Kunming, China, in the Asia region.

How does Walvax Biotechnology make money?

Four revenue lines are on record. Vaccine Sales (Domestic China) is the primary driver. The others are international Vaccine Export, technology Transfer and Licensing and international Development Funding.

Who are Walvax Biotechnology's main competitors?

Direct peers on record are Bharat Biotech, Sinovac Biotech, CanSino Biologics, Hualan Biological Engineering and Zhifei Biological Products. Biological E is listed as an emerging player. Broad incumbents are China National Biotec Group (CNBG/Sinopharm), Serum Institute of India, Pfizer (Prevnar franchise) and Merck (Gardasil franchise).

Does Walvax Biotechnology have an API?

No public API is recorded for Walvax Biotechnology.

What industry is Walvax Biotechnology in?

Walvax Biotechnology's product category is Vaccines. Its primary akta.pro industry code is HLAAAEAA, Prophylactic Human Vaccines (routine, pediatric, adult). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Chinaventure19 A-share vaccine companies' half-year assessment: 11 companies saw revenue decline, the industry is under pressure, does the mRNA cancer vaccine bring new opportunities?Half-year results for 19 A-share vaccine companies show 11 with declining operating income and 9 with falling net profit, while Liaoning Chengda led profit growth at 125.77%. The industry faces pressure from vaccine hesitancy, but Merck and Moderna's mRNA anti-tumor vaccine Intismeran showed positive Phase III results in August 2026.MorningstarCellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical TrialCellOrigin presented two solid-tumor cell therapy candidates at ASCO 2026: CAR-Mix and TMT Engager, both showing preclinical efficacy. The company also partnered with Walvax for an in vivo CAR clinical trial in hepatocellular carcinoma, with the first patient dosed in early 2026.Caixin GlobalChina’s Vaccine Exports Rebound as Drugmakers Look AbroadChina's vaccine exports rebounded in 2025, rising 53.5% in value to 2.318 billion yuan and 130.5% in volume to 357.84 tons, marking the first simultaneous increase in both metrics since the COVID-19 pandemic. Key players like Walvax Biotechnology saw international revenue grow 35% despite an 8% decline in total vaccine revenue, while Beijing Wantai won approval for China's first domestic nine-valent HPV vaccine in June 2025, ending Merck's eight-year monopoly in that market. Chinese pharmaceutical firms are intensifying overseas expansion amid domestic stagnation, with nine vaccines now holding WHO prequalification to facilitate entry into global procurement markets.CaspianpostUzbekistan, Chinese Biopharma Giant Walvax Discuss Plans to Launch Local Vaccine ProductionDuring an official visit to China, a delegation from Uzbekistan met with Walvax Biotechnology Co., Ltd to discuss establishing local vaccine production in Uzbekistan. The discussions focused on technology transfer, product registration, and selecting reliable partners, with Walvax expressing strong interest in a sustainable partnership prioritizing local manufacturing and expansion into Central Asian markets. Both sides committed to deepening cooperation, with the partnership anticipated to significantly advance Uzbekistan's pharmaceutical sector and bolster its national healthcare system.PR NewswireThe China Vaccine Market is Expected to Surpass $12.16 Billion by 2027A market research report projects China's vaccine market will surpass US$12.16 billion by 2027, growing at a compound annual growth rate of 11.97% from its 2022 valuation of US$6.91 billion. The report identifies Sinopharm Group, Sinovac Biotech, Walvax Biotechnology, and other Chinese manufacturers as major players in a market that produces approximately 700 million vaccine doses annually. China's vaccine industry, though historically less mature than US or European counterparts, is expected to enter what analysts describe as a "golden decade" for biopharmaceuticals.PR NewswireGlobal Meningococcal Vaccines Market to Reach $5.1 Billion by 2027 at a CAGR of 9.25%The global meningococcal vaccines market was valued at US$ 3.0 billion in 2021 and is expected to reach US$ 5.1 billion by 2027, with a CAGR of 9.25%. The market growth is driven by increased disease prevalence, routine immunization adoption, and product innovations, amidst ongoing research and healthcare infrastructure improvements.ReutersMexico to begin phase three trials of Sanofi, Walvax COVID-19 vaccinesMexico's health regulator approved phase three trials for Sanofi and Walvax COVID-19 vaccines, with trials starting soon. The country will have 40 million doses by June, rising to 65 million by July. Mexico's own Patria vaccine will enter phase two trials, with possible emergency use approval this year.PR NewswireSirnaomics Enters Partnership with Walvax Biotechnology to Co-Develop Its Antiviral RNAi Therapeutic Product Candidate STP702Sirnaomics entered a partnership with Walvax to co-develop its anti-influenza siRNA candidate STP702, out-licensing exclusive development and commercialization rights in China, Taiwan, Hong Kong, and Macao. The deal includes an initial payment of approximately $6.4 million, with additional milestone payments and royalty sharing based on product sales.FierceBiotechSirnaomics nabs a major $105M funding round for next stage of its RNA workSirnaomics raised $105 million in a Series D round co-led by Rotating Boulder Fund, Walvax Biotechnology, and Sunshine Riverhead Capital. The funding follows positive phase 2a results for its RNAi candidate STP705 in squamous cell carcinoma in situ. The company plans to use the funds for R&D and aims for an IPO.